Merck has recently achieved a significant phase 2 win, boosting investor confidence amidst challenges in its vaccine business and competition for its blockbuster cancer drug Keytruda. The company’s acquisition of Acceleron Pharma for $11.5 billion resulted in the approval of sotatercept, marketed as Winrevair, which has generated $976 million in revenue in 2025. Additionally, sotatercept successfully completed a phase 2 study for a rare form of pulmonary hypertension, potentially adding over $1 billion to its annual sales potential. Merck’s acquisitions of Cidara Therapeutics and progress in developing a new HIV treatment further enhance its growth prospects.

Read more at Nasdaq: Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?